Coronaridine

Coronaridine, an iboga type alkaloid, inhibits the wnt signaling pathway by decreasing β-catenin expression^[1]. In Vitro: Coronaridine (0-40 μM; 24 hours) is against non-cancer cells with IC₅₀ values >40 μM. It agaisnt wnt-dependent cells with IC₅₀ values of 10.4, 11.6 and 24.4 μM for SW480, HCT116 and DLD1cells, respectively^[1].
Coronaridine (0-40 μM; 24 hours) inhibits β-catenin expression, but the protein levels of p-β--catenin at Ser33, Ser37, and Thr41 and p-β-catenin at Ser 45 [p-b-catenin (S45)] are unchanged^[1].
In whole-cell patch clamp recordings,Catharanthine (1-300 μM) are respectively co-applied with GABA at concentrations corresponding to the EC₃₀ value for each receptor subtype. Both congeners potentiated different GABAARs in a concentration-dependent manner^[2].
At higher concentrations, however, Catharanthine starts to inhibit GABA-activated currents due to the reduced amplitude and rebound current, where the threshold concentration depended on the receptor subtype (e.g., > 30 μM for hα1β2; > 100 μM for hα1β2γ2 and hα2β2γ2). The PAM activity of Catharanthine's are depended on the receptor subtype: hα1β2 (4.6±0.8 μM), >hα2β2γ2 (12.6±3.8 μM), hα1β2γ2 (14.4 ± 4.6 μM)^[2].